explore -WSS

explore

author：knowledge 2025-10-04 06:32:56 - browse：77722

Miniature people figurines standing in a group looking down. -- health tech coverage from STAT — Adobe

In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： WHO may add ‘noma' to its list of neglected tropical diseases

WSS

Chimpanzees, like humans and whales, get menopause: Study

Cassava reveals details — and problems — with Alzheimer's study

Colonoscopy prep: Liquid

App could help diagnose ear infections more accurately — and at home

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

SCOTUS questions limit to govt efforts to fight misinformation

hotspot

explore

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Bluebird, CVS, Contineum

Jerome Adams on the need for new antivirals for Covid

Cassava reveals details — and problems — with Alzheimer's study

23andMe had bad news about my health. I wish a person had delivered it

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

knowledge

Paying for Covid pills will soon shift to insurers

Orchard's therapy for neuron disease in children wins FDA approval

Biden's order seeks to regulate AI risk without stifling innovation

Readout Newsletter: XBI biotech index, Akero Therapeutics

CDC recommends rationing of RSV shot due to shortages

Biden's order seeks to regulate AI risk without stifling innovation

entertainment

focus

explore

hotspot